Arkansas’s first-of-its-kind law requiring drug makers to honor 340B pricing when covered entities use contract pharmacies to dispense 340B drugs is not preempted by the federal 340B statute since the state law applies only to the acquisition and delivery of
…
A federal district judge in Washington, D.C., put drug manufacturer Merck’s 340B contract pharmacy lawsuit against the federal government on hold until after a federal circuit court in Washington rules in Novartis and United Therapeutics’ 340B contract pharmacy cases.
Lawyers
…
340B HIV provider groups have slammed a recent federal court decision that could have far-reaching implications on access to a host of preventive health care services.
On Sept. 7, Judge Reed O’Connor of the United States District Court for the
…
A federal appeals court in Chicago will hear oral arguments in drug manufacturer Eli Lilly’s 340B contract pharmacy lawsuit against the federal government on Oct. 31, the court announced on Tuesday.
The half-hour session will take place one week after
…
Key stakeholders have offered federal healthcare officials conflicting advice about how best to respond to the U.S. Supreme Court’s June decision striking down a nearly 30% cut in Medicare Part B drug reimbursement for hospitals’ 340B-purchased drugs.
Tuesday was the
…
Late last month, the U.S. Health Resources and Services Administration (HRSA) said on its website that generic drug manufacturer Unichem Pharmaceuticals USA had to repay 340B covered entities for overcharges found during a 340B program compliance audit.
According to Unichem,
…
About 8.3% of people in the United States, or 27.2 million, had no health insurance at any point during 2021, down from an estimated 8.6%, or 28.3 million, in 2020, the U.S. Census Bureau reported Tuesday.
The National Center for
…
A federal district judge has dismissed two community health centers’ federal and state antitrust claims against four insulin and diabetes drug manufacturers over the companies’ denials of 340B pricing when covered entities use contract pharmacies.
Chief Judge Elizabeth Wolford of
…
Today is the deadline for public comments on Medicare’s proposed rule for how it will pay for hospital outpatient services and clinician-administered drugs in 2023.
340B stakeholders will be paying close attention to comments on how Medicare Part B should
…
Eighty percent of all hospitals in Medicare’s outpatient prospective payment system—including 52% of all 340B hospitals—would see their net OPPS payments decline next year if Medicare ends a nearly 30% cut in 340B hospitals’ drug payments that began in 2018,
…*Sign up for news summaries and alerts from 340B Report